Evidence map›Paper›PMID 41719511›Full record

ArticleJCO precision oncology2026

Larotrectinib in Patients With Tumors With

Neal Akhave, Zihe Song, David S Hong, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06390852 (MATCH Treatment Subprotocol Z1E), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06390852 phase2active not recruitingnot on this map

MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2017 to 2026Enrolled16ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid NeoplasmArmsBiopsy Procedure, Biospecimen Collection, Computed Tomography, Larotrectinib, Magnetic Resonance Imaging
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Neal AkhaveThe University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1291-0218
Zihe SongDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
David S HongThe University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1073-1531
Robert J GrayDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.ORCID 0000-0002-5724-4917
Victoria WangDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
Lisa M McShaneBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-8195-3206
Larry V RubinsteinBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9720-9737
David R PattonCenter for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3855-0166
P Mickey WilliamsFrederick National Laboratory for Cancer Research, Frederick, MD.
Stanley R HamiltonCity of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-8331-1052
Naoko TakebeDevelopmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-5790-4954
James V TricoliCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3975-8516
Barbara A ConleyCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1445-1684
Carlos L ArteagaUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.
Lyndsay N HarrisCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9774-6719
Peter J O'DwyerUniversity of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-9302-4073
Alice P ChenDevelopmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-2919-4326
Keith T FlahertyMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-3402-0478

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2M
NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820
6 · The paper itself

Abstract

purposeRecurrent chromosomal fusions in neurotrophic tropomyosin receptor kinase (

methodsFrom August 21, 2017, to July 8, 2021, patients with solid tumors or lymphomas progressing on standard therapy were genomically profiled and enrolled to NCI-MATCH, a genomically driven, signal-seeking, precision medicine platform trial. They were assigned to subprotocol Z1E if a

resultsIn total, 12 patients with centrally confirmed

conclusionNCI-MATCH subprotocol Z1E demonstrates that larotrectinib offers clinically significant benefit with marked ORR across

Indexed as

NeoplasmsPyrazolesPyrimidinesAdultAgedFemaleHumansMaleMiddle AgedOncogene Proteins, FusionReceptor, trkAlarotrectinibOncogene Proteins, FusionPyrazolesPyrimidinesReceptor, trkA

Identifiers

PMID41719511
PMCPMC12931858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.